Miniatura

Fitxers

1-s2.0-S0261561425000275-main.pdf (480.32 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-02-17

Llicència de publicació

cc-by-nc-nd (c) Joly, Francisca et al., 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/221349

Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.clnu.2025.01.026

Resum

Background and aim: Teduglutide is a glucagon-like peptide-2 analogue used to promote intestinal rehabilitation and decrease the dependence from intravenous supplementation (IVS) in patients with short bowel syndrome and intestinal failure (SBS-IF). The aim of this study was to gain a better understanding of international real-world Teduglutide use since its launch. Methods: Data from an international multicenter database for chronic IF were analysed. All the adult patients with SBS-IF included by centers that treated at least one patient with Teduglutide during the study period (2015-2022) were investigated. The baseline characteristics and the outcome of patients treated with Teduglutide (n.269) were compared to those of patients not receiving the drug (Controls, n.3081). The center experience was categorized based on the number of patients treated with Teduglutide: <10 or >= 10. Results: Teduglutide cohort exhibited higher male prevalence, younger age, longer duration of HPN, higher percentage of SBS with jejunocolonic anastomosis, lower IVS volume, improved oral intake, and higher percentage of patients weaned from IVS. Controls showed higher percentages of patients deceased or lost to follow up. Centers with >= 10 patients treated with Teduglutide showed higher weaning rates and lower mortality rates. Conclusions: This is the largest analysis of Teduglutide's real-world setting in SBS-IF. Clinicians preferentially selected for treatment patients with better prognostic indicators. Outcomes were significantly better in centers with higher Teduglutide treatment volumes, emphasizing the need for specialized referral centers to optimize care for SBS-IF patients. (c) 2025 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Matèries

Malalties de l'aparell digestiu, Terapèutica

Matèries (anglès)

Digestive system diseases, Therapeutics

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

JOLY, Francisca, JEZERSKI, Denise, PAPE, Ulrich-frank, CRIVELLI, Adriana, HUETTERER, Elisabeth, BERGOIN, Charlotte, SASDELLI, Anna simona, AIMASSO, Umberto, SCHNEIDER, Stéphane m., POULLENOT, Florian, SEGUY, David, CHAPMAN, Brooke, SOBOCKI, Jacek, REGANO, Nunzia, LAMPRECHT, Georg, LAYEC, Sabrina, SANTARPIA, Lidia, KOZJEK, Nada rotovnik, GALLITELLI, Livia, LÓPEZ URDIALES, Rafael, FEHR, Rebecca, ITZHAKI, Moran hellerman, MAÍZ JIMÉNEZ, María, CAREY, Sharon, TAUS, Marina, FRANCINI PESENTI, Francesco, RASMUSSEN, Henrik h., VANUYTSEL, Tim, CUERDA COMPES, Cristina, THIBAULT, Ronan, CHEN, Mona, OSLAND, Emma, KRZNARIC, Zeljko, MARTINS DA ROCHA, Mariana hollanda, MARTINUZZI, Andrés l. n., BEZMAREVIC, Mihailo, BUENO DIEZ, Marta, LIVOVSKY, Dan m., SERRANO AGUAYO, Pilar, ORLANDONI, Paolo, BURGOS PELÁEZ, Rosa, CAMPOS MARTÍN, Cristina, ELLEGARD, Lars, LEZO, Antonella, RAMOS BOLUDA, Esther, GANDULLIA, Paolo, BLUETHNER, Elizabeth, ZARPELLON, Martina, LAL, Simon, PIRONI, Loris. Real-world experience of Teduglutide use in adults with short bowel syndrome: A seven-year international multicenter survey. _Clinical Nutrition_. 2025. Vol. 47, núm. 54-67. [consulta: 24 de gener de 2026]. ISSN: 0261-5614. [Disponible a: https://hdl.handle.net/2445/221349]

Exportar metadades

JSON - METS

Compartir registre